CELL · Bruker Cellular Analysis, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.06M | $18.52M | - | $21.40M | $19.15M | $20.21M | - | $24.32M | $19.25M | $18.63M |
| Cost of Revenue | $8.02M | $5.09M | - | $6.37M | $6.22M | $6.38M | - | $8.91M | $6.52M | $3.80M |
| Gross Profit | $6.04M | $13.43M | - | $15.03M | $12.93M | $13.83M | - | $15.41M | $12.73M | $12.45M |
| R&D | $9.34M | $8.42M | - | $8.98M | $18.18M | $17.57M | - | $16.20M | $13.54M | $10.98M |
| SG&A | $26.26M | $26.55M | - | $26.52M | $13.02M | $11.72M | - | $12.26M | $11.72M | $4.00M |
| Total Operating Expenses | $53.25M | $36.26M | - | $36.56M | $38.47M | $35.10M | - | $35.39M | $30.58M | $18.21M |
| D&A | $2.50M | $2.10M | - | $2.20M | $2.50M | $1.94M | - | $1.30M | $1.40M | $1.32M |
| Operating Income | ($47.21M) | ($22.83M) | - | ($21.54M) | ($25.55M) | ($21.27M) | - | ($19.98M) | ($17.85M) | ($8.23M) |
| Interest Expense | $1.63M | $384.0K | - | $229.0K | $227.0K | $224.0K | - | $232.0K | $356.0K | $357.0K |
| Income Tax | $51.0K | $20.0K | - | $22.0K | $4.0K | $20.0K | - | $54.0K | $26.0K | $16.0K |
| Net Income | ($50.24M) | ($23.42M) | - | ($21.57M) | ($25.75M) | ($21.43M) | - | ($20.40M) | ($18.15M) | ($15.44M) |
| EPS - Basic | ($0.51) | ($0.31) | - | ($0.32) | ($0.38) | ($0.32) | - | ($0.16) | ($0.27) | - |
| EPS - Diluted | ($0.51) | ($0.31) | - | ($0.32) | ($0.38) | ($0.32) | - | ($0.16) | ($4.25) | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.96M | $51.61M | $86.52M | $120.64M | $143.02M | $164.67M | $178.10M | $197.00M | $215.08M | $230.16M |
| Accounts Receivable | $14.38M | $25.12M | $18.53M | $20.25M | $13.81M | $17.72M | $25.94M | $24.71M | $19.76M | $16.43M |
| Inventory | $41.45M | $45.54M | $18.86M | $15.71M | $15.66M | $15.66M | $14.55M | $13.21M | $12.57M | $10.94M |
| Accounts Payable | $18.63M | $17.05M | $10.09M | $7.92M | $8.50M | $8.02M | $8.20M | $12.82M | $8.73M | $6.93M |
| Current Assets | $94.79M | $131.64M | $176.95M | $180.96M | $192.47M | $208.36M | $230.57M | $245.91M | $255.52M | $265.78M |
| Total Assets | $178.33M | $300.56M | $226.09M | $234.88M | $248.71M | $265.86M | $287.25M | $301.15M | $295.71M | $302.95M |
| Current Liabilities | $42.23M | $47.44M | $45.49M | $34.38M | $29.14M | $27.71M | $32.75M | $34.31M | $27.49M | $39.61M |
| Long-term Debt | $0 | $14.86M | - | - | - | - | - | - | - | - |
| Total Liabilities | $67.05M | $142.82M | $84.04M | $76.70M | $74.29M | $72.66M | $79.04M | $80.97M | $63.88M | $60.59M |
| Stockholders' Equity | $111.28M | $157.74M | $142.06M | $158.18M | $174.42M | $193.20M | $208.22M | $220.19M | $231.84M | $242.37M |
| Retained Earnings | ($435.31M) | ($385.07M) | ($361.65M) | ($332.35M) | ($310.78M) | ($285.03M) | ($263.61M) | ($245.88M) | ($225.47M) | ($207.32M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($19.55M) | - | - | - | ($10.07M) | - | - | - | ($9.99M) |
| Investing Cash Flow | - | $5.74M | - | - | - | ($4.38M) | - | - | - | ($760.0K) |
| Financing Cash Flow | - | $48.99M | - | - | - | $1.02M | - | - | - | $21.0K |
| CapEx | - | $414.0K | - | - | - | $4.38M | - | - | - | $760.0K |
| Free Cash Flow | - | ($19.97M) | - | - | - | ($14.44M) | - | - | - | ($10.75M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 43.0% | 72.5% | - | 70.2% | 67.5% | 68.4% | - | 63.4% | 66.1% | 66.8% |
| Operating margin | -335.7% | -123.3% | - | -100.6% | -133.4% | -105.3% | - | -82.1% | -92.7% | -44.2% |
| EBITDA margin | -317.9% | -112.0% | - | -90.4% | -120.3% | -95.7% | - | -76.8% | -85.4% | -37.1% |
| Net margin | -357.3% | -126.5% | - | -100.8% | -134.4% | -106.0% | - | -83.9% | -94.3% | -82.9% |
| Free cash flow margin | - | -107.8% | - | - | - | -71.5% | - | - | - | -57.7% |
| FCF / Net income | - | 0.85 | - | - | - | 0.67 | - | - | - | 0.70 |
| R&D / Revenue | 66.4% | 45.5% | - | 42.0% | 94.9% | 87.0% | - | 66.6% | 70.3% | 58.9% |
| SG&A / Revenue | 186.7% | 143.4% | - | 124.0% | 68.0% | 58.0% | - | 50.4% | 60.9% | 21.5% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -28.2% | -7.8% | - | -9.2% | -10.4% | -8.1% | - | -6.8% | -6.1% | -5.1% |
| Return on equity | -45.2% | -14.8% | - | -13.6% | -14.8% | -11.1% | - | -9.3% | -7.8% | -6.4% |
| Return on invested capital | -33.5% | -10.4% | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.24 | 2.77 | 3.89 | 5.26 | 6.61 | 7.52 | 7.04 | 7.17 | 9.30 | 6.71 |
| Quick ratio | 1.26 | 1.81 | 3.48 | 4.81 | 6.07 | 6.95 | 6.60 | 6.78 | 8.84 | 6.43 |
| Cash ratio | 0.73 | 1.09 | 1.90 | 3.51 | 4.91 | 5.94 | 5.44 | 5.74 | 7.82 | 5.81 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.09 | - | - | - | - | - | - | - | - |
| Debt / Assets | 0.00 | 0.05 | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -28.9x | -59.5x | - | -94.0x | -112.5x | -95.0x | - | -86.1x | -50.1x | -23.0x |
| Equity multiplier | 1.60 | 1.91 | 1.59 | 1.48 | 1.43 | 1.38 | 1.38 | 1.37 | 1.28 | 1.25 |
| Liabilities / Assets | 0.38 | 0.48 | 0.37 | 0.33 | 0.30 | 0.27 | 0.28 | 0.27 | 0.22 | 0.20 |
| Efficiency | ||||||||||
| Asset turnover | 0.08 | 0.06 | - | 0.09 | 0.08 | 0.08 | - | 0.08 | 0.07 | 0.06 |
| Inventory turnover | 0.19 | 0.11 | - | 0.41 | 0.40 | 0.41 | - | 0.67 | 0.52 | 0.35 |
| Days sales outstanding | 373d | 495d | - | 346d | 263d | 320d | - | 371d | 375d | 322d |
| Days inventory outstanding | 1887d | 3267d | - | 900d | 919d | 896d | - | 541d | 704d | 1051d |
| Days payable outstanding | 848d | 1223d | - | 454d | 498d | 459d | - | 525d | 488d | 666d |
| Cash conversion cycle | 1412d | 2539d | - | 791d | 683d | 758d | - | 387d | 590d | 707d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -26.6% | -8.4% | - | -12.0% | -0.5% | 8.5% | - | 55.3% | 82.1% | - |
| Revenue CAGR (3y) | 10.0% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -53.2% | -2.9% | - | -2.5% | 1.6% | 11.1% | - | 20.3% | 33.0% | - |
| Operating income growth (YoY) | -84.8% | -7.3% | - | -7.8% | -43.1% | -158.5% | - | -367.0% | -218.6% | - |
| Net income growth (YoY) | -95.1% | -9.3% | - | -5.7% | -41.8% | -38.8% | - | -137.2% | -115.5% | - |
| EPS growth (YoY) | -34.2% | 3.1% | - | -100.0% | 91.1% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -38.2% | - | - | - | -34.4% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -36.2% | -18.4% | -31.8% | -28.2% | -24.8% | -20.3% | -14.9% | -12.1% | 159.5% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$170.78M totalAntibody Therapeutics$64.32M · 37.7%
Product$56.58M · 33.1%
Service$28.81M · 16.9%
Synthetic Biology$8.96M · 5.2%
Gene Therapy$7.11M · 4.2%
Cell Therapy$2.82M · 1.7%
Agricultural Biology$2.18M · 1.3%
Geographic
$85.39M totalNorth America$41.23M · 48.3%
Asia Pacific$35.22M · 41.2%
Europe$8.94M · 10.5%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Bruker Cellular Analysis against the 5 most active filers in the same SIC group.